Skip to main content
    D

    Dyne Therapeutics Inc (DYN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    -0.46 (-2.68%)

    Market Cap: $3.22B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Dyne Therapeutics Inc (DYN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Dyne Therapeutics (DYN) to earn -$3.90 per share in the fiscal year ending Dec 31, 2026. Of 17 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.06, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.

    RatingAnalystsShare
    Strong Buy317.6%
    Buy1270.6%
    Hold15.9%
    Sell00.0%
    Strong Sell15.9%
    Consensus
    Buy
    Total analysts
    17

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$3.90
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$3.54
    EPS consensus, revenue $54.33M
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.90-$4.00 to -$3.839N/AN/A15
    Dec 31, 2027-$3.54-$4.53 to -$2.7513$54.33MN/A15

    Quarterly Estimates

    The EPS consensus falls from -$0.99 for the quarter ending Dec 31, 2026 to -$1.00 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.99-$1.06 to -$0.8917N/AN/A16
    Mar 31, 2027-$1.00-$1.08 to -$0.916$3.00M$125000 to $8.95M6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 5 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202713
    Quarter ending Mar 31, 202712

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.55.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.90-$3.53-$3.55-$3.55-$3.55N/A
    Fiscal year ending Dec 31, 2027-$3.54-$3.31-$3.34-$3.33-$3.26N/A
    Quarter ending Mar 31, 2027-$1.00-$0.84-$0.84-$0.80-$0.80N/A

    Frequently Asked Questions About DYN

    What is the DYN stock forecast?

    Consensus analyst estimates put Dyne Therapeutics's EPS at -$3.90 for the fiscal year ending Dec 31, 2026. The consensus rating from 17 analysts is Buy.

    How do analysts rate DYN stock?

    Of 17 analysts covering Dyne Therapeutics, 3 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from DYN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.90, with estimates from -$4.00 to -$3.83 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.54, with estimates from -$4.53 to -$2.75 from 13 analysts.

    What revenue do analysts expect from Dyne Therapeutics next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $54.33M.

    How many analysts cover DYN?

    17 analysts rate Dyne Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.